mATG-207

mATG-207 is a preclinical recombinant fusion protein developed by Antengene. It serves as the mouse surrogate version of ATG-207, a first-in-class bifunctional fusion protein designed to treat T cell-mediated autoimmune diseases. mATG-207 consists of an anti-CD3 antibody fused to a peptide-masked, TGFβRIII-biased TGF-β domain. By targeting CD3, the molecule localizes to the T cell surface, where it drives spatially restricted, CD3-dependent TGF-β signaling. It preferentially binds to TGF-β receptor type III (TGFβRIII) over TGFβRII, promoting regulatory T cell (Treg) differentiation and suppressing pathogenic effector T cells while minimizing systemic, off-target TGF-β toxicity. In preclinical studies, mATG-207 has demonstrated therapeutic efficacy in mouse models of experimental autoimmune encephalomyelitis (EAE) and inflammatory bowel disease (IBD).